172 related articles for article (PubMed ID: 12177095)
21. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
23. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
24. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
25. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
26. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
27. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
28. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
29. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
30. New drugs for breast cancer.
Smith IE
Lancet; 2002 Sep; 360(9335):790-2. PubMed ID: 12241842
[No Abstract] [Full Text] [Related]
31. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
Trunet P; Marty M
Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
[TBL] [Abstract][Full Text] [Related]
32. [Hormone therapy and breast cancer: a review].
Lucchi-Angellier E
Rev Med Interne; 2001 Dec; 22(12):1213-24. PubMed ID: 11794892
[TBL] [Abstract][Full Text] [Related]
33. Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.
Iwase H
Int J Clin Oncol; 2015 Apr; 20(2):249-52. PubMed ID: 25666484
[No Abstract] [Full Text] [Related]
34. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
Holli K;
Eur J Cancer; 2002 Nov; 38 Suppl 6():S37-8. PubMed ID: 12409068
[No Abstract] [Full Text] [Related]
35. With maturity comes confidence: EBCTCG tamoxifen update.
Chia SK; Wolff AC
Lancet; 2011 Aug; 378(9793):747-9. PubMed ID: 21802719
[No Abstract] [Full Text] [Related]
36. [Antiestrogenic agents for treatment of advanced breast cancers].
Kimura M
Nihon Rinsho; 2000 Apr; 58 Suppl():311-6. PubMed ID: 11026011
[No Abstract] [Full Text] [Related]
37. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
38. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
39. [2nd European Breast Cancer Conference, Bruxelles, September 26-30, 2000. Interview with Anthony Howell].
Howell A
Tumori; 2000; 86(6):A1-4. PubMed ID: 11271673
[No Abstract] [Full Text] [Related]
40. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]